Last reviewed · How we verify

ACA Continuation — Competitive Intelligence Brief

ACA Continuation (ACA Continuation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ACA Continuation (ACA Continuation) — French Innovative Leukemia Organisation. ACA Continuation works by continuing the effects of ACA.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACA Continuation TARGET ACA Continuation French Innovative Leukemia Organisation phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACA Continuation — Competitive Intelligence Brief. https://druglandscape.com/ci/aca-continuation. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: